Specific targeting and noninvasive magnetic resonance imaging of an @entity565 biomarker in the lung using XXXX functionalized magnetic nanocarriers.

@entity1 @entity10328 @entity9597 @entity4047 @entity55 @entity19 @entity565 @entity1933 @entity3646 @entity970 @entity968
UNASSIGNED: Simultaneous inhibition of @entity3646 and @entity4047 via the common receptor chain @entity9597 to block adequately their biologic effects presents a promising therapeutic approach to give the additional relief required for @entity565 @entity1 . In this study, superparamagnetic @entity1933 nanoparticles were conjugated with anti- @entity9597 blocking antibodies via @entity968 ( @entity970 ) polymers. The delivery of these blocking antibodies to the inflammatory sites in the lung via the developed nanocarriers was assessed using noninvasive free-breathing pulmonary MRI. Biocompatibility assays confirmed the safety of the developed nanocarriers for pre-clinical investigations. For all the investigated formulations, nanocarriers were found to be very stable at neutral pH. However, the stability noticeably decreased with the @entity970 length in acidic environment and thus the loaded antibodies were preferentially released. Immunofluorescence and fluorimetry assays confirmed the binding of the nanocarriers to the @entity9597 @entity565 biomarker. Pulmonary MRI performed using an ultra-short echo time sequence allowed simultaneous noninvasive monitoring of inflammatory responses induced by @entity10328 challenge and tracking of the developed nanocarriers, which were found to colocalize with the inflammatory sites in the lung. Targeting of the developed nanocarriers to areas rich in @entity9597 positive inflammatory cells was confirmed using histological and flow cytometry analyses. The anti- @entity9597 -conjugated nanocarriers developed here have been confirmed to be efficient in targeting key inflammatory cells during chronic @entity55 following intrapulmonary administration. Targeting efficiency was monitored using noninvasive MRI, allowing detection of the nanocarriers' colocalizations with the inflammatory sites in the lung of @entity10328 -challenged asthmatic @entity19 . Copyright    2015 John Wiley _ Sons, Ltd.
